Is it possible that GTCB is not viewed as a pure biotech but more of a drug manufacturing company using goats? GTCB just doesn't have the attention of investing community at this time because using goats to manufacture existing proteins isn't "sexy". It is my opinion that until GTCB attracts a major AMERICAN pharmaceutical company to endorse (ie partner with or hire GTCB) its novel approach to manufacturing drugs, we won't see any growth in shareholder value. I am sure GTCB's management is hard at work in trying to line up potential partners.